Evolution of protease inhibitor resistance in the gag and pol genes of HIV subtype G isolates

Journal of Antimicrobial Chemotherapy

Volumn 65, Issue 7, 2010, Pages 1472-1476

  Knops, Elena ^a   Däumer, Martin ^b   Awerkiew, Sabine ^a   Kartashev, Vladimir ^c   Schülter, Eugen ^a   Kutsev, Sergey ^c   Brakier Gingras, Léa ^d   Kaiser, Rolf ^a   Pfister, Herbert ^a   Verheyen, Jens ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b Technische University   (Germany)

^c ROSTOV STATE MEDICAL UNIVERSITY   (Russian Federation)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Gag cleavage site mutations; Gag non cleavage site mutations; Non B subtypes

Indexed keywords

DIDANOSINE; EFAVIRENZ; GAG PROTEIN; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; POL PROTEIN; PROTEINASE INHIBITOR; SAQUINAVIR; STAVUDINE; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; GENE EXPRESSION REGULATION; GENE MUTATION; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN CLEAVAGE; TREATMENT FAILURE; VIRUS ISOLATION; VIRUS RESISTANCE; AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; DNA SEQUENCE; DRUG EFFECTS; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS; ISOLATION AND PURIFICATION; MISSENSE MUTATION; MOLECULAR EVOLUTION; MOLECULAR GENETICS; RUSSIAN FEDERATION; VIROLOGY;

AMINO ACID SUBSTITUTION; DRUG RESISTANCE, VIRAL; EVOLUTION, MOLECULAR; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; MOLECULAR SEQUENCE DATA; MUTATION, MISSENSE; POL GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; POLYMORPHISM, GENETIC; PROTEASE INHIBITORS; RUSSIA; SEQUENCE ANALYSIS, DNA;

EID: 77954191122     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkq129     Document Type: Article

References (13)

1. Nijhuis M, van Maarseveen NM, Lastere S et al. A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism. PLoS Med 2007; 4:e36.
2. Nijhuis M, van Maarseveen NM, de Jong D et al. Substitutions within Gag but outside the cleavage sites can cause protease inhibitor resistance. In: Abstracts of the Fifteenth International HIV Drug Resistance Workshop, Sitges, Spain, 2006. Antivir Ther 2006; 11 Suppl 1: S149. Abstract 133.
3. Parry CM, Kohli A, Boinett CJ et al. Gag determinants of fitness and drug susceptibility in protease inhibitor-resistant human immunodeficiency virus type 1. J Virol 2009; 83: 9094-101.
4. De Meyer S, Azijn H, Fransen E et al. The pathway leading to TMC114 resistance is different for TMC114 compared with other protease inhibitors. In: Abstracts of the Fifteenth International HIV Drug Resistance Workshop, Sitges, Spain, 2006. Antivir Ther 2006; 11 Suppl 1: S24. Abstract 19.
5. Nijhuis M, Schipper P, King M et al. Changes in HIV Gag and protease cannot explain persistent viraemia in the majority of patients failing first-line lopinavir/ritonavir therapy. In: Abstracts of the Sixteenth International HIV Drug Resistance Workshop, Barbados, West Indies, 2007. Antivir Ther 2007; 12 Suppl 1: S146. Abstract 133.
6. Nijhuis M, Novel HIV. gag based protease drug resistance mechanism caused by an increased processing of the NC/p1 cleavage site. In: Abstracts of the Fourteenth International HIV Drug Resistance Workshop, Quebéc, Canada, 2005. Antivir Ther 2005; 10 Suppl 1: S117. Abstract 107.
7. Dam E, Quercia R, Glass B et al. Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss. PLoS Pathog 2009; 5: e1000345.
8. Bobkov A, Garaev MM, Rzhaninova A et al. Molecular epidemiology of HIV-1 in the former Soviet Union: analysis of env V3 sequences and their correlation with epidemiologic data. AIDS 1994; 8: 619-24.
9. Dulude D, Berchiche YA, Gendron K et al. Decreasing the frameshift efficiency translates into an equivalent reduction of the replication of the human immunodeficiency virus type 1. Virology 2006; 345: 127-36.
10. Verheyen J, Litau E, Sing T et al. Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy experienced patients. Antivir Ther 2006; 11: 879-87.
11. Callebaut C, Stray K, Tsai L et al. In vitro HIV-1 resistance selection to GS-8374, a novel phosphonate protease inhibitor: comparison with lopinavir, atazanavir and darunavir. In: Abstracts of the Sixteenth International HIV Drug Resistance Workshop, Barbados, West Indies, 2007. Antivir Ther 2007; 12 Suppl 1: S18. Abstract 16.
12. Dierynck I, De Meyer S, Cao-Van K et al. Impact of Gag cleavage site mutations on the virological response to darunavir/ritonavir in treatment-experienced patients in POWER 1, 2 and 3. In: Abstracts of the Sixteenth International HIV Drug Resistance Workshop, Barbados, West Indies, 2007. Antivir Ther 2007; 12 Suppl 1: S23. Abstract 21.
13. Verheyen J, Knops E, Kupfer B et al. Prevalence of C-terminal gag cleavage site mutations in HIV from therapy-naïve patients. J Infect 2009; 58:61-7.